Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

430 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis.
Mak LY, Gane E, Schwabe C, Yoon KT, Heo J, Scott R, Lee JH, Lee JI, Kweon YO, Weltman M, Harrison SA, Neuschwander-Tetri BA, Cusi K, Loomba R, Given BD, Christianson DR, Garcia-Medel E, Yi M, Hamilton J, Yuen MF. Mak LY, et al. Among authors: gane e. J Hepatol. 2023 Apr;78(4):684-692. doi: 10.1016/j.jhep.2022.11.025. Epub 2022 Dec 10. J Hepatol. 2023. PMID: 36513186 Clinical Trial.
TLR7 agonist RO7020531 versus placebo in healthy volunteers and patients with chronic hepatitis B virus infection: a randomised, observer-blind, placebo-controlled, phase 1 trial.
Yuen MF, Balabanska R, Cottreel E, Chen E, Duan D, Jiang Q, Patil A, Triyatni M, Upmanyu R, Zhu Y, Canducci F, Gane EJ. Yuen MF, et al. Among authors: gane ej. Lancet Infect Dis. 2023 Apr;23(4):496-507. doi: 10.1016/S1473-3099(22)00727-7. Epub 2022 Dec 9. Lancet Infect Dis. 2023. PMID: 36509100 Clinical Trial.
Joint statement in support of hepatitis C human challenge studies.
Alter HJ, Barnes E, Biondi MJ, Cox AL, Eberts JD, Feld JJ, Liang TJ, Morrison J, Rice CM, Shoukry NH, Thomas DL, Van Gennip J, Weijer C; other signatories. Alter HJ, et al. Lancet Gastroenterol Hepatol. 2023 Nov;8(11):967-969. doi: 10.1016/S2468-1253(23)00314-X. Epub 2023 Sep 21. Lancet Gastroenterol Hepatol. 2023. PMID: 37742699 No abstract available.
Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection.
Matthews GV, Bhagani S, Van der Valk M, Rockstroh J, Feld JJ, Rauch A, Thurnheer C, Bruneau J, Kim A, Hellard M, Shaw D, Gane E, Nelson M, Ingiliz P, Applegate TL, Grebely J, Marks P, Martinello M, Petoumenos K, Dore GJ; REACT study group; Protocol Steering Committee; Coordinating Centre; Site Principal Investigators. Matthews GV, et al. Among authors: gane e. J Hepatol. 2021 Oct;75(4):829-839. doi: 10.1016/j.jhep.2021.04.056. Epub 2021 May 21. J Hepatol. 2021. PMID: 34023350 Free PMC article.
Chronic Hepatitis B Finite Treatment: Similar and Different Concerns With New Drug Classes.
Peters MG, Yuen MF, Terrault N, Fry J, Lampertico P, Gane E, Hwang C, Stamm LM, Leus M, Maini MK, Mendez P, Lonjon-Domanec I, Berg T, Wang S, Mishra P, Donaldson E, Buchholz S, Miller V, Lenz O. Peters MG, et al. Among authors: gane e. Clin Infect Dis. 2024 Apr 10;78(4):983-990. doi: 10.1093/cid/ciad506. Clin Infect Dis. 2024. PMID: 37633256 Free PMC article.
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M, Lee HC, Yopp AC, Zhou J, Wang L, Wen X, Heo J, Tak WY, Nakamura S, Numata K, Uguen T, Hsiehchen D, Cha E, Hack SP, Lian Q, Ma N, Spahn JH, Wang Y, Wu C, Chow PKH; IMbrave050 investigators. Qin S, et al. Lancet. 2023 Nov 18;402(10415):1835-1847. doi: 10.1016/S0140-6736(23)01796-8. Epub 2023 Oct 20. Lancet. 2023. PMID: 37871608 Clinical Trial.
Pathway to global elimination of hepatitis B: HBV cure is just the first step.
Howell J, Seaman C, Wallace J, Xiao Y, Scott N, Davies J, de Santis T, Adda D, El-Sayed M, Feld JJ, Gane E, Lacombe K, Lesi O, Mohamed R, Silva M, Tu T, Revill P, Hellard ME. Howell J, et al. Among authors: gane e. Hepatology. 2023 Sep 1;78(3):976-990. doi: 10.1097/HEP.0000000000000430. Epub 2023 May 1. Hepatology. 2023. PMID: 37125643 Free PMC article. Review.
Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions.
Marshall AD, Willing AR, Kairouz A, Cunningham EB, Wheeler A, O'Brien N, Perera V, Ward JW, Hiebert L, Degenhardt L, Hajarizadeh B, Colledge S, Hickman M, Jawad D, Lazarus JV, Matthews GV, Scheibe A, Vickerman P, Dore GJ, Grebely J; Global HCV and HIV Treatment Restrictions Group. Marshall AD, et al. Lancet Gastroenterol Hepatol. 2024 Apr;9(4):366-382. doi: 10.1016/S2468-1253(23)00335-7. Epub 2024 Feb 15. Lancet Gastroenterol Hepatol. 2024. PMID: 38367631 Review.
430 results